Can pharma-shaming get someone re-elected? How rare is too rare when it comes to biotech research? And what does “positive” even mean, really?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we discuss some confusing new clinical data in Alzheimer’s disease that has led to controversy around a Biogen-developed treatment for Alzheimer’s disease. STAT’s Lev Facher joins us to discuss how the issue of drug pricing is shaping races across the U.S. ahead of the midterm elections. And then we explore how crowdfunded science for ultra-rare diseases has led to some inspiring stories and shined a light on a gray area in biotech research. Finally, we run through a packed week of biotech earnings, a hotly contested new depression treatment, and mounting competition in the monopolistic world of genome sequencing.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy